gip glp 1 dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Fair Allocation of GLP-1 and
Description
Nutr., 2015 )

Zhao et al., 2006) and to improve LV function in dogs with dilated cardiomyopathy (Nikolaidis et al., 2005a), in which GLP-1 also attenuated reperfusion-related mechanical ventricular dysfunction not associated with irreversible myocardial damage (myocardial stunning) (Nikolaidis et al., 2005b)

Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al

GLP-1 drugs are expensive enough to be out of reach for most people, unless they're covered by insurance